The U.S. Food and Drug Administration (FDA) has released a new draft guidance on Container Closure Systems for Human Drugs and Biological Products in August 2026. The document provides guiding principles for evaluating the quality of container closure systems used for human drugs and biological products.

Although the document is currently a draft and is provided for comment purposes, it is an important development for pharmaceutical manufacturers, packaging suppliers, and companies involved in drug product development.

What Is a Container Closure System?
A container closure system is more than simply the container that holds a pharmaceutical product. It includes the components that together provide protection for the drug product during storage and use.

According to the FDA draft guidance, the packaging system should provide adequate protection without adversely affecting the safety, identity, strength, quality, or purity of the drug product. The guidance also highlights the importance of selecting packaging materials that do not introduce harmful or undesirable substances into the product.

For pharmaceutical manufacturers, this means that packaging selection needs to be considered as an important part of overall product quality.

Why Does This Matter for Pharmaceutical Packaging?
Pharmaceutical products can be sensitive to environmental conditions such as moisture, oxygen, light, contamination, and interaction with packaging materials.

Therefore, pharmaceutical packaging needs to do more than provide a convenient container.

It should help protect the product throughout its intended shelf life while remaining suitable for the formulation and intended use.

This is particularly important for topical pharmaceutical products such as ointments, creams, and gels, where the compatibility between the formulation and the packaging material can be an important consideration.

Material Compatibility Is an Important Consideration
The FDA draft guidance discusses the evaluation of packaging components and the need to consider potential interactions between the drug product and the container closure system.

For pharmaceutical packaging manufacturers, this highlights the importance of understanding:

• Material compatibility
• Product-package interactions
• Chemical stability
• Container integrity
• Packaging component quality
• Manufacturing controls
• Stability testing
The appropriate evaluation depends on the specific drug product, formulation, packaging design, and intended use.

What Does This Mean for Pharmaceutical Aluminum Tubes?
Aluminum tubes are widely used for pharmaceutical ointments, creams, gels, and other topical products because they provide a practical packaging format and can offer strong protection for the product.

However, choosing an aluminum tube for a pharmaceutical product should not be based only on dimensions or appearance.

Manufacturers and packaging buyers should also consider the tube material, internal coating, tube integrity, manufacturing environment, quality controls, and compatibility with the pharmaceutical formulation.

Xinrontube manufactures pharmaceutical-grade collapsible aluminum tubes for ointments, creams, gels, and lotions. Its production environment includes ISO 8 cleanrooms, with continuous monitoring of environmental conditions during production.

Why Packaging Suppliers Need to Pay Attention
The latest FDA draft guidance is a useful reminder that pharmaceutical packaging is closely connected to product quality.

For pharmaceutical companies evaluating a packaging supplier, important questions may include:

1. What materials are used to manufacture the tube?
2. How is the internal coating controlled?
3. What quality tests are performed?
4. How is contamination controlled during production?
5. Can the supplier provide compatibility or stability-related support?
6. Does the packaging supplier have experience with pharmaceutical applications?
7. Can the supplier provide appropriate regulatory documentation?
A packaging supplier that understands these requirements can become more than a component supplier—it can become a long-term pharmaceutical packaging partner.

What Should Pharmaceutical Companies Do Next?
The FDA document is currently a draft and should not be treated as a final regulatory requirement. Companies should review the official FDA document and consider how its principles may relate to their own pharmaceutical development and packaging processes. Comments on the draft are being accepted until October 13, 2026.

For pharmaceutical packaging projects, early communication between the drug manufacturer and packaging supplier can also help identify potential compatibility, quality, and regulatory considerations before commercial production.

Pharmaceutical Aluminum Tube Manufacturing by Xinrontube
Xinrontube focuses on pharmaceutical aluminum tube packaging for ointments, creams, gels, and other healthcare products.

The company operates automated production lines within ISO 8 cleanroom facilities and offers pharmaceutical aluminum tubes in different diameters and capacities. Its existing product range includes 13.5 mm, 16 mm, 19 mm, and 22 mm tube diameters.

For pharmaceutical companies looking for aluminum tube packaging, the right packaging solution should be selected according to the formulation, application, market requirements, and quality expectations.

Contact Xinrontube to discuss your pharmaceutical aluminum tube packaging requirements.